Page contentsPage contents Key facts Decision Key facts Active substance empasiprubart Therapeutic area Nervous system disorders Decision number EMA/PE/0000236239 PIP number EMA/PE/0000236239 Pharmaceutical form(s) Concentrate for solution for infusion Condition(s) / indication(s) Treatment of chronic inflammatory demyelinating polyradiculo-neuropathy Route(s) of administration Intravenous use Contact for public enquiries Argenx E-mail: regulatory@argenx.com Tel. +32 93103400 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 14/04/2025 Compliance check done No Decision EMA/PE/0000236239: EMA decision of 14 April 2025 on the granting of a product specific waiver for empasiprubartAdopted Reference Number: EMADOC-1700519818-2038994 English (EN) (231.64 KB - PDF)First published: 03/07/2026 View Share this page